A Comparison Study of Bioanalytical Methods for Characterization of Anti-Idursulfase Antibodies

References

• Neufeld EF , MuenzerJ. The mucopolysaccharidoses. In : The Metabolic and Molecular Bases of Inherited Disease, Volume III (8th Edition). ScriverCR, BeaudetAL, SlyWS, ValleD ( Eds). McGraw-Hill, NY, USA, 3421–3452 (2001).
   Google Scholar
• Ohashi T . Enzyme replacement therapy for lysosomal storage diseases. Pediatr. Endocrinol. Rev. 10 (Suppl. 1), 26–34 (2012).
   PubMedGoogle Scholar
• Desnick RJ , SchuchmanEH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13, 307–335 (2012).
   PubMed Web of Science ®Google Scholar
• Martin R , BeckM, EngCet al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics121, e377–e386 (2008).
   PubMed Web of Science ®Google Scholar
• Jones SA , AlmassyZ, BeckMet al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the hunter outcome survey (HOS). J. Inherit. Metab. Dis. 32, 534–543 (2009).
   PubMed Web of Science ®Google Scholar
• Young ID , HarperPS. The natural history of the severe form of hunter’s syndrome: a study based on 52 cases. Dev. Med. Child Neurol. 25, 481–489 (1983).
   PubMed Web of Science ®Google Scholar
• Wraith JE , BeckM, GiuglianiRet al. Initial report from the hunter outcome survey. Genet. Med. 10, 508–516 (2008).
   PubMed Web of Science ®Google Scholar
• Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products . US FDA, MD, USA (2014). www.fda.gov/downloads/drugs/guidances/ucm338856.pdf.
   Google Scholar
• Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins . European Medicines Agency, London, UK (2007). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf.
   Google Scholar
• Wang YM , WangJ, HonY, ZhouL, FangL, AhnHY. Evaluating and reporting the immunogenicity impacts for biological products a clinical pharmacology perspective. AAPS J. 18 (2), 395–403 (2015).
   PubMed Web of Science ®Google Scholar
• Yin L , ChenX, ViciniP, RupB, HicklingTP. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell. Immunol. 295, 118–126 (2015).
   PubMed Web of Science ®Google Scholar
• Schweighardt B , TompkinsT, LauKet al. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with morquio A syndrome: results from MOR-004, A Phase III trial. Clin. Ther. 37, 1012–1021 (2015).
   PubMed Web of Science ®Google Scholar
• Langereis EJ , van VliesN, ChurchHJet al. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol. Genet. Metab. 114, 129–137 (2015).
   PubMed Web of Science ®Google Scholar
• Banugaria SG , PraterSN, NgYKet al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet. Med. 13, 729–736 (2011).
   PubMed Web of Science ®Google Scholar
• Kishnani PS , GoldenbergPC, DeArmeySLet al. Cross-reactive immunologic material status affects treatment outcomes in pompe disease infants. Mol. Genet. Metab. 99, 26–33 (2010).
   PubMed Web of Science ®Google Scholar
• Sellos-Moura M , BarzegarS, PanLet al. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J. Immunol. Methods373, 45–53 (2011).
   PubMed Web of Science ®Google Scholar
• Benichou B , GoyalS, SungC, NorfleetAM, O’BrienF. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol. Genet. Metab. 96, 4–12 (2009).
   PubMed Web of Science ®Google Scholar
• Rombach S , AertsJ, PoorthuisBet al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE7, e47805 (2012).
   PubMed Web of Science ®Google Scholar
• Muenzer J , WraithJE, BeckMet al. A Phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8, 465–473 (2006).
   PubMed Web of Science ®Google Scholar
• Muenzer J , BeckM, EngCMet al. Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome. Genet. Med. 13, 95–101 (2011).
   PubMed Web of Science ®Google Scholar
• Barbier AJ , BielefeldB, WhitemanDA, NatarajanM, PanoA, AmatoDA. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase. Mol. Genet. Metab. 110, 303–310 (2013).
   PubMed Web of Science ®Google Scholar
• Pano A , BarbierAJ, BielefeldB, WhitemanDA, AmatoDA. Immunogenicity of idursulfase and clinical outcomes in very young patients (16months to 7.5years) with mucopolysaccharidosis II (Hunter syndrome). Orphanet J. Rare Dis. 50, 1–14 (2015).
   Google Scholar
• Giugliani R , HwuWL, Tylki-SzymanskaA, WhitemanDA, PanoA. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5years) with hunter syndrome receiving idursulfase enzyme replacement therapy. Genet. Med. 16, 435–441 (2014).
   PubMed Web of Science ®Google Scholar
• Muenzer J , HendrikszCJ, FanZet al. A Phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet. Med. 18, 73–81 (2016).
   PubMed Web of Science ®Google Scholar